Hemodynamic Effects of Single-Dose Vardenafil in Subjects Receiving MaravirocVOURVAHIS, Manoli; JUANZHI FANG; HUYGHE, Isabelle et al.Journal of acquired immune deficiency syndromes (1999). 2010, Vol 54, Num 3, pp 336-338, issn 1525-4135, 3 p.Article

Population-Based Sequencing of the V3-loop Can Predict the Virological Response to Maraviroc in Treatment-Naive Patients of the MERIT TrialMCGOVERN, Rachel A; THIELEN, Alexander; JAMES, Ian et al.Journal of acquired immune deficiency syndromes (1999). 2012, Vol 61, Num 3, pp 279-286, issn 1525-4135, 8 p.Article

Pharmacokinetic Interaction of Ritonavir-Boosted Elvitegravir and MaravirocRAMANATHAN, Srinivasan; ABEL, Samantha; TWEEDY, Sarah et al.Journal of acquired immune deficiency syndromes (1999). 2010, Vol 53, Num 2, pp 209-214, issn 1525-4135, 6 p.Article

Maraviroc: point sur les données cliniques récentesREYNES, J.Médecine et maladies infectieuses. 2009, Vol 39, pp 5-9, issn 0399-077X, 5 p., HS1Conference Paper

Maraviroc : The First of a New Class of Antiretroviral AgentsMACARTHUR, Rodger D; NOVAK, Richard M.Clinical infectious diseases. 2008, Vol 47, Num 2, pp 236-241, issn 1058-4838, 6 p.Article

Assessment of the pharmacokinetics of co-administered maraviroc and raltegravirANDREWS, Emma; GLUE, Paul; JUANZHI FANG et al.British journal of clinical pharmacology. 2010, Vol 69, Num 1, pp 51-57, issn 0306-5251, 7 p.Article

Hepatic safety and tolerability in the maraviroc clinical development programAYOUB, Ayman; ALSTON, Sam; GOODRICH, James et al.AIDS (London). 2010, Vol 24, Num 17, pp 2743-2750, issn 0269-9370, 8 p.Article

A pharmacokinetic-pharmacodynamic model to optimize the phase IIa development program of maravirocROSARIO, Maria C; POLAND, Bill; SULLIVAN, John et al.Journal of acquired immune deficiency syndromes (1999). 2006, Vol 42, Num 2, pp 183-191, issn 1525-4135, 9 p.Article

Maraviroc and CD4⁺ cell count recovery in patients with virologic suppression and blunted CD4⁺ cell responseLANZAFAME, Massimiliano; LATTUADA, Emanuela; VENTO, Sandro et al.AIDS (London). 2009, Vol 23, Num 7, pp 869-869, issn 0269-9370, 1 p.Article

Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entryWESTBY, Mike; SMITH-BURCHNELL, Caroline; MORI, Julie et al.Journal of virology. 2007, Vol 81, Num 5, pp 2359-2371, issn 0022-538X, 13 p.Article

Maraviroc modelling strategy: use of early phase 1 data to support a semi-mechanistic population pharmacokinetic modelWEATHERLEY, Barry; MCFADYEN, Lynn.British journal of clinical pharmacology. 2009, Vol 68, Num 3, pp 355-369, issn 0306-5251, 15 p.Article

Maraviroc : in vitro assessment of drug-drug interaction potentialHYLAND, Ruth; DICKINS, Maurice; COLLINS, Claire et al.British journal of clinical pharmacology. 2008, Vol 66, Num 4, pp 498-507, issn 0306-5251, 10 p.Article

A Pilot Trial of Adding Maraviroc to Suppressive Antiretroviral Therapy for Suboptimal CD4⁺ T-Cell Recovery Despite Sustained Virologic Suppression: ACTG A5256WILKIN, Timothy J; LALAMA, Christina M; GULICK, Roy et al.The Journal of infectious diseases. 2012, Vol 206, Num 4, pp 534-542, issn 0022-1899, 9 p.Article

Antiviral effect of maraviroc in semen: a case reportPASQUIER, Christophe; MOINARD, Nathalie; SAUNE, Karine et al.Antiviral therapy (London). 2012, Vol 17, Num 5, pp 933-936, issn 1359-6535, 4 p.Article

Cerebrospinal fluid maraviroc concentrations in HIV-1 infected patientsYILMAZ, Aylin; WATSON, Victoria; ELSE, Laura et al.AIDS (London). 2009, Vol 23, Num 18, pp 2537-2540, issn 0269-9370, 4 p.Article

Assessing theoretical risk and benefit suggested by genetic association studies of CCR5 : experience in a drug development programme for maravirocWHEELER, Jeremy; MCHALE, Mary; JACKSON, Vicky et al.Antiviral therapy (London). 2007, Vol 12, Num 2, pp 233-245, issn 1359-6535, 13 p.Article

Innate immunity cell activation in virologically suppressed HIV-infected maraviroc-treated patientsDENTONE, Chiara; DI BIAGIO, Antonio; FILACI, Gilberto et al.AIDS (London). 2014, Vol 28, Num 7, pp 1071-1074, issn 0269-9370, 4 p.Article

Maraviroc Reduces the Regulatory T-Cell Frequency in Antiretroviral-Naive HIV-Infected SubjectsPOZO-BALADO, Maria Mar; MARTINEZ-BONET, Marta; ROSADO, Isaac et al.The Journal of infectious diseases. 2014, Vol 210, Num 6, pp 890-898, issn 0022-1899, 9 p.Article

Impact of adding maraviroc to antiretroviral regimens in patients with full viral suppression but impaired CD4 recoverySTEPANYUK, Olena; CHIANG, Tom S; DEVER, Lisa L et al.AIDS (London). 2009, Vol 23, Num 14, pp 1911-1913, issn 0269-9370, 3 p.Article

Pharmacocinétique clinique du maraviroc = Clinical pharmacokinetic of maravirocPEYTAVIN, G.Médecine et maladies infectieuses. Supplément. 2008, Vol 38, Num 1, issn 1166-8237, S12-S16Article

Discordance rates between Trofile^® test and short-term virological response to maravirocGENEBAT, Miguel; RUIZ-MATEOS, Ezequiel; GONZALEZ-SERNA, Alejandro et al.Antiviral research. 2011, Vol 89, Num 2, pp 182-185, issn 0166-3542, 4 p.Article

Stratégies thérapeutiques antirétrovirales non conventionnelles en première ligne du traitement de l'infection par le VIH-1 = Toward new strategies for first-line antiretroviral treatment of HIV-1 infected patientsDELAUGERRE, Constance; GHOSN, Jade.Virologie (Montrouge). 2012, Vol 16, Num 6, pp 371-380, issn 1267-8694, 10 p.Article

CD4⁺ T-Cell Restoration After 48 Weeks in the Maraviroc Treatment-Experienced Trials MOTIVATE 1 and 2ASMUTH, David M; GOODRICH, James; COOPER, David A et al.Journal of acquired immune deficiency syndromes (1999). 2010, Vol 54, Num 4, pp 394-397, issn 1525-4135, 4 p.Article

Raltegravir Plasma Concentrations in Treatment-Experienced Patients Receiving Salvage Regimens Based on Raltegravir With and Without Maraviroc CoadministrationBARONCELLI, Silvia; VILLANI, Paola; GALLUZZO, Clementina M et al.The Annals of pharmacotherapy. 2010, Vol 44, Num 5, pp 838-843, issn 1060-0280, 6 p.Article

Primary resistance to maraviroc in a large set of R5-V3 viral sequences from HIV-1-infected patientsSECLEN, Eduardo; DEL MAR GONZALEZ, María; LAPAZ, Mariana et al.Journal of antimicrobial chemotherapy (Print). 2010, Vol 65, Num 12, pp 2502-2504, issn 0305-7453, 3 p.Article